Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Aflibercept in Uveal Melanoma: NCT06121180 Clinical Landscape Report 2026
16 October 2026
NCT06121180 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Sarcoma: NCT06116578 Clinical Landscape Report 2026
16 October 2026
NCT06116578 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pucotenlimab in Renal Cell Carcinoma: NCT06129955 Clinical Landscape Report 2026
16 October 2026
NCT06129955 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Hormone receptor positive malignant neoplasm of breast: NCT06120283 Clinical Landscape Report 2026
16 October 2026
NCT06120283 clinical landscape for Hormone receptor positive malignant neoplasm of breast: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
Metabolically Armed CD19 CAR-T cells(Leman Biotech ) in Mediastinal large B-cell lymphoma: NCT06120166 Clinical Landscape Report 2026
16 October 2026
NCT06120166 clinical landscape for Mediastinal large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
NK510 in Metastatic osteosarcoma: NCT06117878 Clinical Landscape Report 2026
16 October 2026
NCT06117878 clinical landscape for Metastatic osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Advanced Triple-Negative Breast Carcinoma: NCT06125080 Clinical Landscape Report 2026
16 October 2026
NCT06125080 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Apatinib Mesylate in Osteosarcoma: NCT06125171 Clinical Landscape Report 2026
16 October 2026
NCT06125171 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TPST-1495 in Endometrial Carcinoma: NCT06129604 Clinical Landscape Report 2026
16 October 2026
NCT06129604 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Soft Tissue Sarcoma: NCT06128863 Clinical Landscape Report 2026
16 October 2026
NCT06128863 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivosidenib in Chondrosarcoma: NCT06127407 Clinical Landscape Report 2026
16 October 2026
NCT06127407 clinical landscape for Chondrosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ST-1898 in Advanced Renal Cell Carcinoma: NCT06127238 Clinical Landscape Report 2026
16 October 2026
NCT06127238 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.